Research analysts at CIBC began coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a research report issued on Tuesday, FirstToMarketsRatingsTable reports. The firm set an “outperform” rating and a $26.00 price target on the stock. CIBC’s price target points to a potential upside of 145.28% from the stock’s previous close.
A number of other equities research analysts have also issued reports on the company. ValuEngine lowered Welbilt from a “hold” rating to a “sell” rating in a research report on Wednesday, June 12th. Citigroup set a $12.00 price target on Controladora Vuela Co Avcn SA CV and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Tuesday. Finally, Oppenheimer began coverage on Neurocrine Biosciences in a research report on Tuesday. They issued an “outperform” rating and a $100.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Millendo Therapeutics has a consensus rating of “Buy” and a consensus price target of $24.43.
MLND stock opened at $10.60 on Tuesday. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $12.79. The stock has a market capitalization of $148.32 million, a price-to-earnings ratio of -0.60 and a beta of 2.61. Millendo Therapeutics has a 1 year low of $6.77 and a 1 year high of $17.34.
Millendo Therapeutics (NASDAQ:MLND) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.08). Equities research analysts forecast that Millendo Therapeutics will post -3.25 earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of MLND. Worth Venture Partners LLC purchased a new position in Millendo Therapeutics in the fourth quarter worth approximately $206,000. BlackRock Inc. purchased a new position in Millendo Therapeutics in the fourth quarter worth approximately $203,000. Private Advisors LLC grew its position in Millendo Therapeutics by 9.1% in the first quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after acquiring an additional 1,279 shares during the period. Tibra Equities Europe Ltd purchased a new position in Millendo Therapeutics in the first quarter worth approximately $303,000. Finally, Great Point Partners LLC purchased a new position in Millendo Therapeutics in the fourth quarter worth approximately $10,240,000. Institutional investors and hedge funds own 44.07% of the company’s stock.
About Millendo Therapeutics
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Recommended Story: Quick Ratio
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.